WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has entered into a partnership with the Greater Philadelphia Business Coalition on Health (GPBCH) to make the ILUSTRA Inflammation Management Program available to GPBCH employer-members in the Philadelphia area as part of a company’s enhanced employee benefits plan.
The collaboration is designed to introduce ILUSTRA to coalition members and to assist employer members in implementing and evaluating the innovative ILUSTRA program.
“We’re proud to be working with GPBCH to educate its members on the health benefits that may result from improved employee engagement through the ILUSTRA program,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “This relationship continues to advance our commercial strategy by providing preferred access to this region’s most innovative employers. We are delighted to have our first GPBCH member on board, and are advancing discussions to include other employers.”
“The Greater Philadelphia Business Coalition on Health (GPBCH) is excited to foster this relationship in order to continue to drive better healthcare and wellness for our employer members and their employees. We believe this innovative program has the potential to significantly improve health and lower costs, and we have committed to assist in evaluating the program’s impact in order to share findings and best practices with other interested employers,” said Neil Goldfarb – President and CEO of GPBCH
The ILUSTRA Inflammation Management Program targets individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform - a digital program that delivers engaging, personalized content tailored to maximize engagement and drive compliance and behavior change.
Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs.
About the ILUSTRA Inflammation Management Program
The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation. The program utilizes a genetic test to identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation. Such individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. The program integrates educational outreach to the patient’s care team and provides reminders and content to patients to drive engagement. The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit www.ILUSTRA.com.
About Greater Philadelphia Business Coalition on Health (GPBCH)
The Greater Philadelphia Business Coalition on Health (GPBCH) is an employer membership organization focused on improving employee health, and the quality, safety and value delivered by the healthcare system. The Coalition’s 45 current employer members represent 1.5 million lives nationally. More information is available at www.gpbch.org.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation; its cardiovascular test to guide treatment of high risk patients; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.
Forward-Looking Statements
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation and that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.